FIELD: medicine.
SUBSTANCE: invention describes application of IL-17-binding molecules for producing a drug for growth inhibition of solid malignant proliferative diseases or hematological proliferative diseases. The IL-17-binding molecules include variable domains of heavy and light chains. The molecules include at least one antigen binding site containing variable domains of heavy and light chains of immunoglobulin. The domains consistently include hypervariable CDR regions with certain amino acid sequences. What is described is a method of growth inhibition of solid or haematological malignant proliferative diseases with using the pharmaceutical composition containing the IL-17-binding molecule.
EFFECT: antibodies under the invention are capable to block IL-17 action and are applicable for prevention and treatment of IL-17-mediated diseases, including for inhibition of solid or haematological malignant proliferative diseases.
5 cl, 4 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IL-17 ANTAGONIST ANTIBODIES | 2005 |
|
RU2426741C2 |
| METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS | 2011 |
|
RU2591083C2 |
| METHODS OF TREATING RHEUMATOID ARTHRITIS USING IL-17 ANTAGONISTS | 2011 |
|
RU2582937C2 |
| METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS | 2011 |
|
RU2665954C1 |
| ANTIBODIES TO MST1R AND THEIR APPLICATION | 2010 |
|
RU2534890C2 |
| THERAPEUTIC BINDING MOLECULES | 2002 |
|
RU2328506C2 |
| ANTIBODIES TO HUMAN CSF-1R AND USE THEREOF | 2011 |
|
RU2617971C2 |
| HUMAN INTERLEUKIN 17 (IL-17) ANTIBODIES AND USING THEM | 2009 |
|
RU2539029C2 |
| HUMAN ANTIBODIES TO IL-β1 | 2001 |
|
RU2286351C2 |
| USE OF IL-17 ANTAGONISTS FOR INHIBITION OF STRUCTURAL DAMAGE PROGRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS | 2015 |
|
RU2697383C2 |
